Indri Febriani, Febby Nurdiya Ningsih, Sri Rahayu Lestari, Jodi Suryanggono, Erba Vidya Cikta, Tika Widayanti, Asri Sulfianti, R. Tedjo Sasmono, Sabar Pambudi
Background. Monoclonal antibodies, the main component of antigen-based rapid diagnostic tests, are produced in vitro through hybridoma cell cultivation supplemented with animal-derived serum, such as fetal bovine serum. The supplementation of FBS in culture medium causes controversy due to the variation of components included in FBS per production, potentially reducing the quality of mAbs. Moreover, the cost of using FBS is high. This study aimed to evaluate the growth capacity of hybridoma clones after being adapted to low serum conditions. Methods. The clones SB4 and RD8 producing mAb against spike protein of SARS-CoV-2 were used in this study. Cell kinetics were observed and measured for seven days with 10% and 3% FBS supplementation. Then, the mAbs production was measured semi-quantitatively by indirect enzyme-linked immunosorbent assay. In addition, the cell cycle was also evaluated through flow cytometry analysis at 24 h, 48 h, and 72 h of treatment. This study was conducted with a true-experiment method (n=3), and all quantitative results were statistically analyzed. Results. The results show that supplementation of 3% FBS in these two hybridoma clones gave a different response regarding cell proliferation and productivity. The clone RD8 was excellent in growth kinetics and maintained the mAbs production on low-serum media, while SB4 showed a different pattern. Conclusion. Accordingly, supplementation of 3% FBS may support hybridoma productivity as a fulfilment of mAbs production while considering the characteristics of each hybridoma clone. © (2025), (Hashemite University). All rights reserved.
Research Center for Vaccine and Drugs, National Research and Innovation Agency, South Tangerang, Banten, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Negeri Malang, East Java, Malang, Indonesia; Center of Pharmaceutical and Medical Technology, Agency for the Assessment and Application of Technology (BPPT), South Tangerang, Serpong, Indonesia; Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Cibinong Science Center, West Java, Cibinong, Indonesia
